ZLAB - MCAP CO - Zai Lab Limited

Zai Lab Limited (ZLAB) functions as a strategic hub for implementing Western medical developments in Asia through licensing agreements. Current price action, recorded at 2.81, accompanies the company's expansion. Profit growth is driven by the approval of oncology drugs and access to PRC government programs. The business model relies on the aggressive acquisition of rights to foreign innovations and their subsequent localization.

When constructing a defensive portfolio, fundamental screening begins with an assessment of market capitalization, calculated as the product of the current share price and the total number of shares outstanding. For the biopharmaceutical holding Zai Lab Limited (ZLAB), this metric reflects market confidence in the company's ability to scale global drugs in China, which clearly demonstrates the trend of the company's market capitalization.